CCG-232964 is an orally active inhibitor of Rho/MRTF/SRF . CCG-232964 inhibits LPA-induced CTGF gene expression.
Products | Products > Disease Areas > Cancer | Products > Disease Areas > Neurological, Eye or Ear Disease | Products > Signaling Pathways > Cell Cycle/DNA Damage | Products > Signaling Pathways > TGF-beta/Smad | Products > Signaling Pathways > Stem Cell/Wnt | Products > Signaling Pathways > MAPK/ERK Pathway | Products > Signaling Pathways > Cytoskeleton | Products > Signaling Pathways > GPCR/G Protein | Products > Research Areas > Neurological Disease | Products > Research Areas > Cancer | Products > Research Areas > Cancer > Cancer Targeted Therapy | Products > Research Areas > Cancer > Cancer Stem Cells | Products > Research Areas > Cancer > Cancer Metabolism and Metastasis | Products > Signaling Pathways > ROCK | Products > Signaling Pathways > Ras
Please leave a message for us or use the following ways to contact us, we will reply to you as soon as possible, and provide you with the most sincere service, thank you.